The Department of Neurology at the University of Minnesota (U of M) seeks a board certified/board eligible Neurologist with advanced training and expertise in movement disorders to join the faculty as Clinical Director of the Movement Disorders Division during a time of exciting growth. Protected time for research opportunities will be available for qualified individuals. Additionally, tenure and non-tenure track faculty appointments are available based on interests and qualifications.
The ideal candidate will be an experienced clinician and educator and will possess demonstrable program-building expertise. As the incoming Clinical Director of the Movement Disorders Division and fellowship program, the candidate will have access to world-class research and clinical facilities as well as opportunities to collaborate with internationally recognized movement specialists and physician scientists, particularly in the fields of Parkinson’s and Neuroimaging Research.
Jerrold L. Vitek, MD, PhD
Chairman, Department of Neurology
Professor of Neurology
Dr. Vitek is the Head of the Neurology Department and the Director of the Neuromodulation Research Program at the University of Minnesota. He previously served as the Neuromodulation Research Center Director at the Lerner Research Institute of the Cleveland Clinic Foundation developing functional surgery and deep brain stimulation (DBS) techniques for the treatment of neurological disease. He has also held faculty positions at Emory University and The Johns Hopkins University, where he assisted in the development of the functional neurosurgery programs and conducted research on the pathophysiology of movement disorders and mechanism(s) underlying the beneficial effects of DBS.
Movement Disorders Faculty
The Division of Movement Chief, Anthony J. Santiago, M. D. is an Associate Professor of Neurology, Section Chief of the Divisions of Movement Disorders and Ataxia, and Director of the Movement Disorders Fellowship Program at the University of Minnesota. Previously, he was Associate Professor of Neurology at the Muhammad Ali Parkinson Research Center at Barrow Neurological Institute (MAPRC/BNI), where he served as the National Parkinson Foundation Center Director, Director of the Movement Disorders Fellowship Program and the Director of Clinical and Translational Research in Neurodegenerative Disorders.
Prior to his position at the MAPRC/BNI, he was the Medical Director of the Edward Ewell Parkinson's Disease and Movement Disorders Center in Spokane, WA, a Clinical Associate Professor in the Department of Pharmacotherapeutics at Washington State University (WSU), and the Co-Director of the Pharm D Fellowship in Neurodegenerative Disorders at WSU.
Dr. Santiago is a nationally-recognized clinician and clinical researcher in Movement Disorders and author of numerous peer-reviewed journal articles and book chapters. He is also a frequent lecturer for national organizations supporting research and care initiatives for patients with Parkinson's Disease (Michael J. Fox Foundation, Davis Phinney Foundation, National Parkinson Foundation, Parkinson Disease Foundation) and the recipient of numerous research grants from government and industry partners. Finally, Dr. Santiago is a clinician who emphasizes a holistic and humanistic approach to patient care, partnering with his patients and their families to create a relationship that is mutual and nurturing.
Movement Disorders Team
Scott Cooper, MD, PhD
Assistant Professor of Neurology
After a movement disorders fellowship at Columbia University, Dr. Cooper joined the Movement Disorders group at the Cleveland Clinic, which had one of the earliest large programs in the country for deep brain stimulation (DBS). He 'grew up' with the Cleveland Clinic DBS program becoming a senior neurologist on the DBS team before moving to the University of Minnesota in December 2014. He is a clinical neurologist specializing in movement disorders and a research physiologist specializing in control of voluntary movement.
David Rottenberg, MSc (Cantab), MD
Professor of Neurology
After graduating from Harvard Medical School, Dr. Rottenberg spent two years as a Research Associate at the National Institutes of Health (NIH), trained under Fred Plum and Jerry Posner as a neurologist with special expertise in neuro-oncology, and headed an NIH-and NSF-funded neuroimaging research enterprise for 15 years. In addition to his practice of neurology, now mostly limited to movement disorders and deep brain stimulation, Dr. Rottenberg currently sits on the editorial boards of medical and scientific journals and consult for government and industry.
For the past 30 years his research has focused on quantitative neuroimaging — most notably on CT, PET, MRI and fMRI — computational neuroanatomy, and scientific visualization. In particular he has been interested in the analysis of PET and fMRI time-series data, the generation of surface-based maps of functional activation and cortical thickness, and the creation of computerized methods for visualizing multi-dimensional data at single points in stereotactic anatomical space. He has been involved in the development and evaluation of bias-field-correction and tissue-segmentation algorithms and MRI/fMRI image-processing pipelines, and has used quantitative neuroimaging techniques to study patients with disorders of consciousness, cancer, AIDS, Parkinson's disease, and genetically-defined ataxic disorders.
Paul Tuite, MD
Professor of Neurology
Site Co-Investigator of the MJ Fox BIOFIND
Since arriving at the University of Minnesota in 1996 Dr. Tuite has directed more than 30 clinical trials related to Parkinson's disease (PD) and other movement disorders. In addition to evaluating new therapies, his interests include the development of novel brain MRI and nuclear imaging tests that may aid in the diagnosis of PD, increase our understanding of the disease, and monitor the effects of treatment. Dr. Tuite is also interested in rehabilitation and in developing methods to monitor and improve movements in people with PD. Dr. Tuite is the site co-investigator of an M.J. Fox study entitled BIOFIND that is aiding in the pursuit of a biomarker that can be used in diagnosing and tracking the course of PD. His most recent publications demonstrate the potential utility of N-acetylcysteine in increasing brain and blood glutathione, the brain's most prevalent antioxidant.
David Walk, MD
Associate Professor of Neurology
Director, ALS & Charcot-Marie-Tooth Clinics
Medical Director, Electromyography Lab
Director, Neuromuscular Disorders/Muscle Disease
Dr. David Walk is a neurologist at the University of Minnesota Medical Center Fairview with a subspecialty interest in neuromuscular diseases. Dr. Walk currently directs the University of Minnesota's multidisciplinary ALS and Charcot-Marie-Tooth clinics. Named a "top doctor" by Minneapolis St. Paul Magazine, he believes that the management of neuromuscular disorders requires a team dedicated to providing comprehensive care.
Dr. Walk has been an Associate Professor of Neurology at the University of Minnesota Medical School since 2005 and a staff neurologist at the University of Minnesota Medical Center, Fairview since 1999; he is also the Medical Director of the electromyography laboratory.
Dr. Walk's research interests include ALS and other motor neuron disorders, Charcot-Marie-Tooth disease, and quantitative sensory testing in patients with neuropathic pain.
Dr. Walk's ongoing research projects are focused on ALS as well as sensory evaluation in neuropathy and neuropathic pain. He was the Principal Investigator of a study entitled “Quantitative Sensory Testing in Pathologic Pain States” sponsored by the Minnesota Medical Foundation and the local Principal Investigator of a study sponsored by the University of Minnesota Clinical and Translational Science Institute involving chemotherapy-induced peripheral neuropathy. Ongoing research projects in the neuromuscular section include a longitudinal study of imaging biomarkers in ALS, a prospective evaluation of quantitative sensory testing in pathologic pain, and the assessment of A-delta and C-fiber small nerve function in established chemotherapy-associated neuropathy.
Movement Disorders Laboratory: Colum MacKinnon, PI
The laboratory uses a variety of non-invasive neurophysiological techniques (high-resolution EEG, TMS, tDCS, startle) to probe the cortical, subcortical and spinal mechanisms contributing to movement impairment. In collaboration with colleagues at the Center for Magnetic Resonance Research (CMRR), we are also using brain imaging methods (magnetic resonance imaging, positron emission tomography) to examine the neuroanatomy and neurochemistry of movement disorders. These methods are combined with measures of movement kinematics and kinetics and multi-channel electromyography (EMG) that provide objective quantitative assessment of movement performance. The present focus of research is examining the mechanisms contributing to the two of the cardinal motor symptoms of basal ganglia dysfunction: akinesia (poverty of spontaneous voluntary movement) and bradykinesia (slowing of movement). The laboratory is currently examining the relationship between freezing of gait and sleep disorders in people with Parkinson's disease (funded by the Michael J. Fox Foundation for Parkinson's Research), the mechanisms by which external cues facilitate gait initiation in PD (funded by the NIH), and the mechanisms of impaired control of repetitive movement in PD. The goal of the program is to translate this knowledge to the development, testing and implementation of novel therapies and interventions for people with disordered movement.
- Mechanisms of movement Facilitation and Research By Cueing in Parkinson's Disease
- Sponsor: NIH NINDS
- Mechanisms of movement Facilitation and Research By Cueing in Parkinson's Disease
- Control of Repetitive Movement in Parkinson's Disease
- Sponsor: NIH NINDS
- Principal Investigator: Colum D. McKinnon, PhD
- Postdoctoral Fellows
- Chiahao Lu
- Research Coordinators
- Jackie Vachon
- Daniel Corcos (University of Illinois at Chicago)
- Mark Rogers (University of Maryland Baltimore)
- Eric Perrault (Northwestern University)
- John Rothwell (Institute of Neurology, London)
- Jules Dewald (Northwestern University)
- C.J. Heckman (Northwestern University)
- Monica Gorassini (University of Alberta)
Since 1996, the MD Center's purpose has been to improve research, clinical, and teaching activities related to muscle disease. The center is part of the Academic Health Center at the University of Minnesota, and for the past ten years has co-sponsored the Annual Muscular Dystrophy Center Symposium that attracts more than 100 researchers and participants and features distinguished, internationally recognized speakers. The MD Center faculty members have 20 NIH grants, 2 NIH training grants and more than $25 million in total direct costs for muscle related research. This includes the largest T32 Training Program in the country for muscle research led by PI Dave Thomas, PhD and the Muscular Dystrophy Center Core Laboratories, led by PI James Ervasti, PhD.
The MD Center, one of 5 MD Centers of Excellence for Duchenne Clinical Research, collaborates with other educational institutions, government agencies, private sectors, and non-profit organizations to facilitate research, education, and service activities related to muscular dystrophies. The center is also home to one of only two NIH P30s and one of only two NIH P01s for Muscular Dystrophy research. The center’s collaboration with local resources such as the Muscular Dystrophy Association (MDA), Gillette Children's Hospital, and University of Minnesota Medical Center Fairview facilitate outreach and clinical services.
The University of Minnesota Health Clinics and Surgery Center recently opened its doors on February 22 of this year. The 342,000-square-foot facility houses 37 medical subspecialties, from primary care to neurology and orthopedics. The building is also home to the Masonic Cancer Clinic, infusion center, lab and imaging services, a retail pharmacy, café, an outpatient surgery center and other clinical services.
The state-of-the-art Clinics and Surgery Center is an unprecedented opportunity for University of Minnesota Health to reimagine the outpatient experience for patients. For starters, the building design is flexible and modular, which allows the clinical spaces to adjust on a day-to-day basis to accommodate the number of patients needing a specific service. Housing many specialties under a single roof also promotes greater communication between the specialists on different care teams. In fact, the building is equipped with “collaboration spaces” where care providers from one or more specialties can meet together to discuss patient care. Often, patients are able to coordinate their appointments with different specialists in order to increase the efficiency of their visits. The diagnostic and treatment services are often located adjacent to or near our clinical services, which means patients won’t have to go far for necessary medical tests.
To incorporate the latest research and medical innovations into patient care, we’ve also created a Discovery Experience at the Clinics and Surgery Center. Video monitors will promote clinical trials and other research opportunities in the center, and patients can use kiosks throughout the building to access StudyFinder, a website that will help them find relevant health research opportunities.
Department of Neurology
Jerrold L. Vitek, MD, PhD
Chairman, Department of Neurology
Professor of Neurology
The Department has a long and storied tradition of committed leadership: starting from the direction of internationally-renowned A.B Baker, MD, PhD - who was instrumental in founding the American Academy of Neurology and served as its first president in 1948 - through the current Chair, Jerrold Vitek, MD, PhD. There has been a strong commitment to providing outstanding patient care, engaging in novel and impactful scientific investigations, fulfilling the academic mission of recruiting the best, brightest and most motivated applicants and supporting their transition to independent careers as neurologists and neuroscientists. The Department of Neurology is comprised of more than 45 physician and physician scientist faculty members that provide patient care at four public teaching hospitals throughout the Twin Cities. Across the public teaching hospitals, the Department cares for more than 3,000 inpatient evaluations and 10,000 outpatient visits each year.
Since its inception in 1946, the Department has been dedicated to high quality clinical care and internationally recognized research oriented accomplishments, obtained in large measure due to the effective embracement of interdisciplinary/interdepartmental collaboration. Today, interdisciplinary collaboration crosses all major disciplines including Neurosurgery, Psychiatry, Pediatrics, Psychology, Pharmacy, Radiology/Neuroradiology, ENT, Biomedical Engineering and Neuroscience. The Department also collaborates with colleagues in the Center for Magnetic Resonance Research (CMRR), the Institute of Human Genetics, the Division of Epidemiology and Community Health (School of Public Health), and the Brain Sciences Center and Geriatric Research and Education Clinical Center (GRECC) at the Minneapolis VA Medical Centers. Additionally, a new program in vestibular and balance disorders is being developed and will be interdisciplinary oriented.
Research & Teaching
The University of Minnesota is a world-class research institution with a well-established medical school that dates back to 1888. The University pioneered medical discoveries like the first external pacemaker, the first successful bone marrow transplant, the first successful open-heart surgery, and the world’s first stem cell institute. The University of Minnesota’s Twin Cities campus also ranked No. 8 in public research institutions in the United States based on the Center for Measuring University Performance (CMUP)’s 2013 report.
Research is a critical element in the fight against neurological disease; it paves the way for the development and implementation of new therapies and provides opportunities to expand our academic mission. Our physicians pioneer new surgical therapies for Parkinson's disease and dystonia and the application of deep brain stimulation for movement and psychiatric disorders, and multidisciplinary studies in diseases of muscle and nerve with a world-class Center for Magnetic Resonance Imaging illustrate the critical role played by research in the delivery of clinical care.
The academic faculty are distributed among four public teaching hospitals: the University of Minnesota Medical Center, Fairview (UMMC); Hennepin County Medical Center (HCMC); the Minneapolis Veterans Administration Hospital (VAMC); and Regions Medical Center (Regions). Diverse patient populations constitute a major strength of our clinical, research and training programs. Across the public teaching hospitals, the Department cares for more than 1,000 neurology inpatients per year, provides 2,000 inpatient consultations, and accounts for 10,000 outpatient visits.
Neurosciences and Research at the U
Institute for Translational Neuroscience (ITN)
The Institute for Translational Neuroscience (ITN) was established in 2007 as a University-wide presidential initiative to promote the transfer of discoveries in the basic neurosciences to clinical practice. The institute is charged to enhance basic science discovery with new knowledge leading to subsequent clinical trials and establishment of new therapeutic principles or tools.
The ITN grew out of the University of Minnesota Presidential Initiative on Brain Function across the Lifespan. It was advanced by the external review of neuroscience in February 2006 and by the work of a Leadership Advisory Committee, chaired by Deborah Powell in her capacity as the former assistant vice president for clinical sciences, that worked from July through December 2006.
In February 2007, Frank Cerra, former senior vice president for health sciences officially inaugurated the institute. In his charge to the institute's steering committee, he outlined four thematic areas that seek to connect basic neuroscientific discovery to improving clinical care and new treatments and therapies. The four areas are: neuroengineering, neurodevelopment and mental health, neurodegenerative and neuromuscular diseases, and memory research and care. Since 2011, the four areas have evolved to include imaging via the high powered magnets in the Center for Magnetic Resonance Research. These themes represent the breadth of strength and opportunity in the translational neurosciences across the University.
Harry Orr, PhD
Professor of Laboratory Medicine & Pathology
Tulloch Professor of Genetics
Director, Institute of Translational Neuroscience
Dr. Harry Orr’s research is focused on the molecular genetics of neurodegenerative diseases, principally the autosomal dominant form of spinocerebellar ataxia (SCA1). Patients usually develop SCA1 in mid-life. They experience loss of motor coordination and develop slurred speech, spasticity, and cognitive impairment. Orr and his colleagues cloned the SCA1 gene and found that the disease is caused by the expansion of an unstable, repeated cytosine-adenine-guanine (CAG) sequence in DNA. Orr and his colleagues established the first transgenic mouse model for SCA1 with which they were able to induce ataxia with Purkinje cell features characteristic of SCA1 by inserting CAG repeats. The model has helped his team understand how the SCA1 mutant polyglutamine protein, ataxin-1, moves from the cytoplasm into the nucleus of Purkinje cells where together with other protein complexes it causes Purkinje dendrites to atrophy. They found that phosphorylation of a specific ataxin-1 serine results in greater stabilization of the mutant protein, which alters the normal ratio of stabilized versus degraded protein and results in aberrant binding and disease. When human trials begin, the hope is that a sufficient number of therapeutic molecules will be taken in by Purkinje cell terminals and transferred to the cell bodies to be beneficial to patients.
Biomedical Discovery District
The Biomedical Discovery District (BDD) is a complex of research buildings designed to allow researchers from across the Academic Health Center to work side-by-side in order to find cures, treatments, and prevention of diseases. The various facilities are comprised of state-of-the-art space to fight today’s health challenges. Each facility hosts basic and translational research areas that span from hearing, vision, and stem cells to infectious disease, neuroscience, and immunology. The newest facility opened in 2013 and hosts cancer and cardiovascular research.
CTSI: Clinical and Translational Science Institute
Bruce R. Blazar, MD
Director, Clinical & Translational Science Institute
Director, Center for Translational Medicine
Vice Dean for Clinical Investigation
AHC Associate Vice President for Clinical & Translational Science
CRF Chair in Pediatric Oncology
Chief, Pediatric Blood & Marrow Transplantation Program
About the CTSI
The Clinical and Translational Science Institute (CTSI) at the University of Minnesota's Academic Health Center is supported through the National Institutes of Health Clinical and Translational Science Award (CTSA) program, grant UL1TR000114. The institute is one of approximately 60 medical research institutions working together to improve the way clinical and translational research is conducted nationwide, enhancing its efficiency and quality. The CTSA consortium aims to accelerate the process of translating laboratory discoveries into treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and translational researchers. Its goals are to create an academic home and an adaptive, sustainable infrastructure to support clinical translational science research at the University of Minnesota; foster meaningful relationships and transparent interactions among the U of M and the communities; and to train and reward interdisciplinary clinical translational science teams at the U of M and in the communities.
About the CTSA award
The CTSA Consortium is a national consortium of approximately 60 Clinical and CTSA institutions that have committed to improve human health by streamlining science, transforming training environments, and improving the conduct, quality, and dissemination of clinical and translational research.
Programs & Initiatives
Our efforts focus on meeting investigators’ needs, and creating an efficient, effective research infrastructure at the University. Here are a few ways we’re doing this:
- Clinical Data Repository: Houses the electronic medical records of more than 2 million patients, which can be accessed for health-related research, including grant applications, studies, participant recruitment, and more.
- StudyFinder: A recruitment-focused website that makes it easier than ever for the general public to find and connect with University health studies that need volunteers, to help researchers attract the participants they need for their studies.
- Research Toolkit: An online resource that houses research tools, templates, information, and guidance from a wide range of sources, to help investigators navigate the University research process.
- Child health research: An initiative led by Child Health Champion Mark Schleiss, MD, brings together community and University child health researchers to explore opportunities for collaborative research.
We regularly team up with other CTSAs to increase the efficiency and speed of clinical and translational research. Highlights of these joint efforts include:
- Midwest Area Research Consortium for Health (MARCH): This collaboration offers investigators a streamlined infrastructure for undertaking studies that are better served collectively, at multiple sites.
- Greater Plains Collaborative: Regional network of 10 leading medical centers that is creating a national data network, with the help of a $7 million grant from the Patient-Centered Outcomes Research Institute (PCORI).
Center for Magnetic Resonance Research (CMRR)
Established in 1991, the CMRR is an interdepartmental and interdisciplinary research laboratory that provides state-of-the-art instrumentation, expertise, and infrastructure to carry out biomedical research utilizing the unique capabilities provided by high field MRI and MRS methodology.
The central aim of the research conducted in CMRR is to non-invasively obtain functional, physiological, and biochemical information in intact biological systems, and use this capability to probe biological processes in health and disease. Which focuses on the development of unique magnetic resonance imaging and spectroscopy methodologies and instrumentation for the acquisition of structural, functional, and biochemical information non-invasively in humans, and utilizing this capability to investigate organ function in health and disease.
Funded by the NIH as a Biotechnology Research Resource for High field Magnetic Resonance Imaging and Spectroscopy, and supported by numerous governmental and private foundations, CMRR core faculty have made significant and pioneering contributions in biological applications of magnetic resonance techniques, and possess unique expertise in very high field uses of this methodology.
CMRR faculty conducts research in a variety of areas including:
- High field functional brain mapping in humans; methodological developments, mechanistic studies, and neuroscience applications
- Metabolism, bioenergetics, and perfusion studies of human pathological states (tumors, obesity, diabetes, hepatic encephalopathy, cystic fibrosis, and psychiatric disorders
- Cardiac bioenergetics under normal and pathological conditions
- Automated magnetic field shimming methods that are critical for spectroscopy and ultrafast imaging at high magnetic fields
- Development of high field magnetic resonance imaging and spectroscopy techniques for anatomic, physiologic, metabolic, and functional studies in humans and animal models
- Radiofrequency (RF) pulse design based on adiabatic principles
- Development of magnetic resonance hardware for high fields (e.g. RF coils, pre-amplifiers, digital receivers, phased arrays, etc.)
- Development of software for data analysis and display for functional brain mapping.
- 10.5 Tesla / 89 cm Bore system for human studies (world’s largest)
- 16.4 Tesla for animal model studies
- 9.5 (2) Tesla for animal model studies
- 7 Tesla (shielded MR System for Human Studies; eye tracking)
- Cyclotron – Siemens PETNET
- 17.0 Tesla 5cm Vertical Bore
- 4 Tesla for human studies
- Siemens Inveon preclinical microPET/CT
- 3 Tesla (multiple, w/advanced imaging)
Neuromodulation Research Center and Lab (NRCL)
The Center for Neuroengineering (CNE) was established in 2007 to enhance neuroengineering research at the University of Minnesota as part of the Institute for Translational Neuroscience. The CNE is now also affiliated with the Institute for Engineering in Medicine. Bridging neuroscience and engineering, neuroeingineering is an emerging field that translates research discoveries into neuro-technologies that provide new and powerful tools for basic and clinical neuroscience research and lead to enhanced patient care. For example, developments in brain-machine interface (BMI) technology exemplify the dramatic progress and potential of neuroengineering. Another successful example is Deep Brain Stimulation (DBS), in which functional electrical stimulation has been demonstrated to treat patients with Parkinson's disease and a host of other nervous system disorders. These two examples demonstrate the feasibility of translating neuroscience findings into technologies that can directly impact patient care.
The NRCL develops multi-scale computational neuron models to further understanding of the biophysical and physiological mechanisms of neuromodulation. In partnership with the Minnesota Supercomputing Institute, the NRCL couples finite element models of electric fields generated in neural tissue with computational neuron models built from sets of mathematical equations that replicate the biophysical properties of membrane and synapse dynamics.
The NRCL also investigates the therapeutic mechanisms of neuromodulation experimentally through multi-channel electrophysiological and neurochemical techniques in animal models of movement disorders. The NRCL is particularly interested to determine how neurons encoding movement are modulated during deep brain stimulation, how stimulation at different therapeutic efficacies influences these neurons, and how the modulation of neuronal firing patterns changes during chronic stimulation.
The NRCL is developing new types of implants and stimulation strategies that are inspired by the underlying neuroscience. The NRCL evaluates these technologies with the goal of leveraging industrial partnerships to translate these therapies from the laboratory to the clinic.
The University of Minnesota has strong, highly recognized research groups in engineering and neuroscience that provide the underpinning for an initiative in neuroengineering. Coupled with the strong medical device industry in Minnesota, the University is uniquely positioned to seize this opportunity to enhance neuroengineering research and translate findings into new technologies and products. The CNE is aimed at bringing together and building upon the rich existing strengths at the University of Minnesota to address the unique opportunity in the emerging field of neuroengineering. The CNE has identified thrust areas of interdisciplinary research and training in neural interfacing and modulation, neuroimaging, and neural computation. The CNE will offer an opportunity to foster on-campus collaborations among faculty in the basic sciences, engineering, and clinical departments as well as collaborations with the biomedical industry.
Center for Neurodegenerative Disease
The overarching goal of the Center for Neurodegenerative Disease is to bring together researchers that have synergistic strengths in basic movement disorder-oriented neuroscience research, and clinical neurosciences. In addition, these researchers collaborate with several different groups including the NINDS Institutional Center Core grant, the Bob Allison Ataxia Research Center, and the Paul and Sheila Wellstone Muscular Dystrophy Center.
N. Bud Grossman Center for Memory Research and Care
The N. Bud Grossman Center for Memory Research and Care is a tripartite endeavor encompassing basic, translational, and clinical research on memory disorders. Our goal is to relieve the suffering caused by Alzheimer's disease. We are working towards safe and affordable prevention strategies and comprehensive care and support for people with memory problems and their families. In order to achieve this goal, we have brought together scientists, physicians and health care workers.
We are one of four centers within the Institute for Translational Neuroscience (ITN), administered within the Medical School which is a division of the Academic Health Center at the University of Minnesota. The center members are drawn from the Departments of Neurology, Neuroscience, and Psychiatry. Our center has strong ties to the Minneapolis Veterans Affairs Health System, Geriatric Research, Education and Clinical Center (VA GRECC) where some faculty have joint appointments and some of our research is performed.
Stem Cell Institute
Established in 1999, the Stem Cell Institute is the first interdisciplinary institute in the United States dedicated to stem cell research. The Institute’s vision is to use stem cell biology to change the practice of medicine through discovery, education, and translation. The researchers and faculty of the SCI explore the science of stem cell biology with the purposes of responding to the medical needs of today and educating the researchers of tomorrow, and together have 16 US patents. The Institute draws together 50 investigators from 22 University departments to participate in stem cell research targeting 5 primary diseases: cancer, diabetes, heart disease, neurological disorders, and inherited disorders.
The University of Minnesota Genomics Center (UMGC) provides genomics research services committed to advancing genomics in Minnesota. The UMGC maintains and acquires state-of-the-art instrumentation and offers an array of services including sequencing, expression, genotyping, nucleic acid extraction, and related support. We strive to keep pace with the ever-broadening world of “omics” technologies (genomics, epigenomics, metabolomics), and to expand our role at the University and the wider biotech community.
The center provides genomics research services for UMN investigators and external companies. Although the primary goal of the UMGC is to provide a diverse portfolio of research services to UMN investigators, we also have a mandate to translate discoveries in genomics to the founding of knowledge-based companies in the State of Minnesota. Additionally, the center assesses and acquires emerging technologies to drive the expansion of biomedical and agricultural research. Genomics technologies evolve at a rapid pace. The efficient and well-planned evaluation and acquisition of new instrumentation is paramount in maintaining a competitive advantage for UMN researchers and external clients.
Minnesota’s Discovery, Research, and Innovation Economy is a landmark partnership between the University and the state of Minnesota that aligns areas of University research strength with the state’s key and emerging industries to address grand challenges. In 2013, the Minnesota Legislature authorized an $18 million recurring annual investment in four research areas identified by University faculty, deans, and corporate partners as the most promising areas for partnership: Robotics, Global Food, Environment and Brain Conditions. The University of Minnesota Informatics Institute (UMII), which fosters and accelerates data-intensive research, receives partial funding from MnDRIVE and provides key support to these projects.
MnDRIVE represents a unique, collaborative research model involving interdisciplinary research projects across the University that address grand challenges and include industry partnerships as a key component. Funding proposals for the four areas of research undergo a rigorous peer review process by a strategic advisory board consisting of representatives from academia, industry and the broader community.
The Office of the Vice President for Research provides accountability measures for the initiative and serves as an advocate for the program at the Legislature. The Vice President for Research also oversees the Transdisciplinary Research Program. Each of the four research areas have committees and advisory boards to oversee project implementation and outreach.
Metrics are tracked and reported across all four areas to assess the impact of MnDRIVE research, education and industry relationships on economic development and quality of life for Minnesotans. To date, MnDRIVE funding has supported 210 projects, produced 41 potential patents or licenses, created 321 jobs and forged more than 75 external partnerships with companies throughout the state, many of which are in the food and agricultural sector.
Human Connectome Project
Mapping of the human connectome offers a unique opportunity to understand the complete details of neural connectivity (Sporns et al., 2005, Wedeen et al., 2008, Hagmann et al., 2007). The Human Connectome Project (HCP) is a project to construct a map of the complete structural and functional neural connections in vivo within and across individuals. The HCP represents the first large-scale attempt to collect and share data of a scope and detail sufficient to begin the process of addressing deeply fundamental questions about human connectional anatomy and variation.
The grants ($40m) are the first awarded under the Human Connectome Project. They will support two collaborating research consortia. The first will be led by researchers at Washington University, St. Louis, and the University of Minnesota, Twin Cities. The other will be led by investigators at Massachusetts General Hospital (MGH)/Harvard University, Boston, and the University of California Los Angeles (UCLA).
Mapping the human brain is one of the great scientific challenges of the 21st century. The Human Connectome Project (HCP) is tackling a key aspect of this challenge by elucidating the neural pathways that underlie brain function and behavior. Deciphering this amazingly complex wiring diagram will reveal much about what makes us uniquely human and what makes every person different from all others.
The consortium led by Washington University, University of Minnesota, and Oxford University (the WU-Minn HCP consortium) is comprehensively mapping human brain circuitry in a target number of 1200 healthy adults using cutting-edge methods of noninvasive neuroimaging. It will yield invaluable information about brain connectivity, its relationship to behavior, and the contributions of genetic and environmental factors to individual differences in brain circuitry and behavior.
The Washington U./Minnesota team will map the connectomes in each of 1,200 healthy adults — twin pairs and their siblings from 300 families. The maps will show the anatomical and functional connections between parts of the brain for each individual, and will be related to behavioral test data. Comparing the connectomes and genetic data of genetically identical twins with fraternal twins will reveal the relative contributions of genes and environment in shaping brain circuitry and pinpoint relevant genetic variation. The maps will also shed light on how brain networks are organized.
Successful charting of the human connectome in healthy adults will pave the way for future studies of brain circuitry during development and aging and in numerous brain disorders. In short, it will transform our understanding of the human brain in health and disease.
University of Minnesota Medical School Leadership
Brooks Jackson, MD, MBA
Vice President of Health Sciences
Dean, Medical School
Dr. Jackson came to the University from Johns Hopkins University School of Medicine, where he served as Director of Pathology for 12 years. Under Jackson, the school's pathology department rose from fifth to first nationwide in NIH funding, with nearly $50 million in annual NIH awards. He completed his residency in pathology at the University of Minnesota, and was happy to have the opportunity to return to lead the Medical School and Academic Health Center into the future. Jackson earned his MD from Dartmouth Medical School and his MBA at Dartmouth College.
An internationally recognized researcher in HIV diagnostics, prevention and treatment, Jackson and his colleagues revolutionized HIV prevention in developing countries and published approximately 200 peer-reviewed papers about HIV prevention and treatment research conducted in the United States, Uganda, and China. He is also the principal investigator of the $500 million NIH-funded International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network. Jackson’s work resulted in new drug development and a project to prevent neonatal HIV transmission. The method has saved thousands of infants from starting life with HIV infection.
President of the University: Eric W. Kaler
Eric W. Kaler, PhD
President, University of Minnesota
Since taking office in 2011, President Eric Kaler has focused on core priorities: academic excellence, access for qualified students, stewardship of tuition and public dollars, a world-class research enterprise that aligns with the needs of the state of Minnesota and its industries, and a deep commitment to public engagement and outreach, locally and globally.
In 2013, in partnership with Minnesota's Legislature, Kaler achieved $35.8 million in research investments from the state. In an initiative called MnDRIVE—the Minnesota Discovery, Research and Innovation Economy program—research emphasis matches some of the University’s research and discovery strengths with the state’s most pressing needs and key industries. That has resulted in 210 separate research projects involving 629 researchers resulting, so far, in 41 invention disclosures, leveraging an additional $57 million in external research funding.
In 2010, Kaler was elected to the National Academy of Engineering, the highest honor for a leader of that discipline and profession, and based on distinguished and continuing achievements in original research. In 2012, Secretary of Homeland Security Janet Napolitano named him to the U.S. Department of Homeland Security Academic Advisory Council, on which he continues to serve. In 2013, he was named a Charter Fellow of the National Academy of Inventors.
Kaler received his Ph.D. in chemical engineering from the University in 1982. He went on to become one of the nation’s foremost experts on “complex fluids,” which have applications in drug delivery, food processing, pharmaceuticals, and manufacturing.
Before coming to the U, Kaler served from 2007 to 2011 as provost and senior vice president for academic affairs at Stony Brook University in Stony Brook, New York. Previously, he was dean of the University of Delaware’s College of Engineering. He also taught at the University of Washington. He received his undergraduate degree from the California Institute of Technology in 1978.
Partnership with Industry
University of Minnesota expands MN-IP program to promote industry partnerships and boost regional economies
To promote technology partnerships with U.S. and Minnesota-based companies, improve access to university-developed technology and boost regional economies the University of Minnesota announced today it is expanding the Minnesota Innovation Partnerships (MN-IP) program to provide easy access to already-developed University technologies and solutions.
Initiated in 2011, MN-IP lowers the cost and risk companies face when sponsoring university research. The original version of the program, now called MN-IP Create, streamlines the process of sponsoring research and licensing intellectual property (IP). It establishes industry-friendly terms up front, granting companies an exclusive worldwide license to the resulting IP. To date, MN-IP Create has resulted in 83 partnerships to develop products and services across industries including biotechnology, pharmaceuticals and medical devices. The industry partners range from small Minnesota startups to large multinational companies.
As part of the MN-IP program expansion, the university today is introducing MN-IP Try and Buy. Try and Buy was developed to provide companies a low-cost, low-risk method to determine the commercial potential behind existing university-developed technologies. Companies will be able to take available technologies for a "test-run" or use them fee-free (if qualified) to test the viability of the innovation for their company. The new program grants companies a low-cost agreement to analyze technology under pre-negotiated licensing terms for a trial period without incurring any U.S. patent costs until a patent issues, and without paying royalties on the first $1 million in revenue. One of the highlights of the new program is the discount allotted to Minnesota companies which reduces fees for the trial period as well as royalty rates for the license
The MN-IP program is part of the university’s ongoing efforts to work more effectively with the business community, and the complementary programs within MN-IP are designed to help set the conditions for economic development, including the creation of new products and jobs, and allow industry to access the university’s researchers and facilities.
The White House’s Office of Science and Technology Policy recently recognized the program for fostering university-industry partnerships and strengthening the United States’ economic competitiveness. "[MN-IP] and other models ... promise to help foster university-industry partnerships and strengthen America’s economic competitiveness."
U of M Selected as Hub for NIH Program to Accelerate New Inventions to the Market
The University of Minnesota has been selected by the National Institutes of Health as one of three Research Evaluation and Commercialization Hub (REACH) sites nationally to establish a university-wide strategic framework promoting commercialization and technology transfer in the life sciences and biomedical technology.
Supported by a $3 million NIH grant with another $3 million in matching U of M funds, the U’s MINREACH program will provide commercial expertise and resources needed for the development and commercialization of diagnostics, therapeutics, preventive medicine and medical devices. Vadim Gurvich, associate director of the college’s Institute for Therapeutics Discovery and Development, will co-lead the pharmaceutical side of the program.
The program will establish new industry partnerships, strengthen existing partnerships, and provide entrepreneurial, commercial-style education for innovators to accelerate the pace at which innovations reach the marketplace. It will fund between 10-20 research projects a year. Under the program, workshops and industry mentors will coach faculty in key aspects of commercialization, including subjects like competition, venture capital and market assessment. Meanwhile, the program will identify and address barriers in the academic environment that may hinder commercialization.
MIN-REACH builds upon several existing, nationallyrecognized programs at the U designed to advance sponsored research and technology commercialization, including Minnesota Innovation Partnerships (MNIP), Discovery Capital and MINCorps, an NSF-funded program that promotes student entrepreneurship in science and engineering. MIN-REACH will also build upon Minnesota’s long history of success in medical innovation, as the state is home to the top 17 publicly traded medical device companies in the U.S. At the U of M, medical innovations are among the most prominent inventions of the U’s commercialization portfolio.
MHealth: Integrated Academic Health System
In the fall of 2015, the University of Minnesota Board of Regents, Fairview Health Services, University of Minnesota Physicians (UMPhysicians) and University of Minnesota boards all signed a Letter of Intent to explore combining Fairview and University of Minnesota Physicians into a fully integrated academic health system. The Letter of Intent signals a commitment of the organizations to work together to improve health, discover new treatments and cures and educate the health workforce, helping people lead longer, healthier lives.
The University of Minnesota has an unparalleled depth and breadth of research and clinical partners that it taps into to provide expert care, knowledge and support.
Those partners include:
- The University of Minnesota Academic Health Center is the gateway to health research, education, and training at the University of Minnesota. It serves six colleges and schools, more than 90 centers and institutes, and University of Minnesota Health hospitals and clinics.
- University of Minnesota’s Clinical and Translational Science Institute (CTSI), holder of the University’s largest ever National Institutes of Health (NIH) grant, provides services, funding, consultations and resources to University and community researchers to help them be more successful and advance their research discoveries. Through the Clinical and Translational Science Award (CTSA) five-year $51 million award in 2011, the University of Minnesota became part of the National Center for Advancing Translational Sciences (NCATS), a consortium of 62 health research sites across the United States.
- University of Minnesota’s Masonic Cancer Center is a comprehensive cancer center designated by the National Cancer Institute, one of only 45 institutions in the United States, that creates a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve quality of life for patients and survivors; and sharing its discoveries with other scientists, students, professionals, and the community.
The University of Minnesota is located in the Twin Cities of Minneapolis and St. Paul, the birth place and headquarters of the American Academy of Neurology (AAN). Four key attributes sets the Minneapolis-Saint Paul region apart: a resilient, diverse economy anchored by 17 Fortune 500 companies, a penchant for innovation, a highly educated workforce – one of the best in the nation and an outstanding quality of life.
The Minneapolis-Saint Paul area is cosmopolitan at its heart and small town along its perimeter. The Twin Cities is the 16th largest metro area in the US, with a population of approximately 3.4 million people. It is the 2nd largest economic center in the Midwest, behind Chicago, and the second largest medical device manufacture center in North America. Minneapolis proper contains the 5th highest concentration of Fortune 500 companies in the country. The presence of the corporate headquarters for companies such as Target, US Bancorp, Xcel Energy and Ameriprise Financial provide a growing economy with great job opportunities for a candidate’s spouse or family. Additionally, an exciting arts and music scene, exceptional shopping, award-winning restaurants, wineries and craft breweries, and distinctive accommodations can be found throughout the area. Outdoor enthusiasts find plenty to do – even when temperatures dip, the variety of fun outdoor adventures does not. Sports fans cheer on their favorite team year-around. Big city bustle or small town charm, anyone can find the activity that suits them in the Minneapolis – Saint Paul Area.
Notable accolades for the Minneapolis-St. Paul area include:
- Hottest travel destinations in 2013 by Leisure and Travel Magazine (Minneapolis listed first)
- CNBC ranked Minnesota as the top state for business in 2015
- 2013 Top Ten Cities to Live in the U.S.by Top10sTop.com
- Monster.com ranks Minneapolis as 4th best for career advancement
- Minneapolis overtook Washington DC in the #1 spot in 2015 to become the most literate city according to USA Today
- USA Today ranks Minneapolis-St. Paul as #1 for the best local food scene in the US
- MSP Airport is the #1 by Travel and Leisure
- Ranked as the 2nd “Best City for a Healthy Retirement”
- Ranked as the 4th “Safest City for Families with Young Children”
- Ranked as the 8th “Best City to Relocate to in America”
- Minneapolis is one of America’s cleanest cities according to a top travel deals publisher
- Minnesota ranks 3rd for quality of life in the U.S. according to Minnesota Public Radio
- Minnesota leads in VC for health care startups according to PR Newswire
- Minneapolis 4th Best in Nation for Health Care according to the Commonwealth Fund
- Twin Cities best placed in U.S. to find employment according to Finance & Commerce
- MSP Airport is #1 Best Airport in America according to Leisure and Travel Magazine
- The Minneapolis–Saint Paul area is home to 16 of Minnesota's 17 Fortune 500 headquarters
- Currently, the Twin Cities is the second largest medical device manufacture center in North America
- In August 2013, Minneapolis–Saint Paul appeared on Forbes magazine's list of Best Places for Business and Careers.